Access to anti-retroviral drugs, male in Madagascar

Madagascar: Access to anti-retroviral drugs, male was 22.0% in 2024. ◆ Volatile

Latest (2024)
22.0%
Change on year
up 29.4%
World rank
139th
of 141 countries
All-time high
22.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Madagascar, 2000–2024

051015202000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 0 %2006: 1 %2007: 1 %2008: 1 %2009: 1 %2010: 1 %2011: 1 %2012: 1 %2013: 1 %2014: 2 %2015: 3 %2016: 4 %2017: 5 %2018: 7 %2019: 9 %2020: 9 %2021: 12 %2022: 15 %2023: 17 %2024: 22 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, male in Madagascar stood at 22.0%. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 29.4% on the previous year and up 1,000.0% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Madagascar peaked at 22.0% in 2024 and was at its lowest, 0.0%, in 2000.

Madagascar ranks 139th of 141 countries on this measure, in the bottom quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Madagascar, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Madagascar, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 0.0%
2006 1.0%
2007 1.0% +0.0%
2008 1.0% +0.0%
2009 1.0% +0.0%
2010 1.0% +0.0%
2011 1.0% +0.0%
2012 1.0% +0.0%
2013 1.0% +0.0%
2014 2.0% +100.0%
2015 3.0% +50.0%
2016 4.0% +33.3%
2017 5.0% +25.0%
2018 7.0% +40.0%
2019 9.0% +28.6%
2020 9.0% +0.0%
2021 12.0% +33.3%
2022 15.0% +25.0%
2023 17.0% +13.3%
2024 22.0% +29.4%

Averages by decade

DecadeAverage LowestHighest Years
2000s 0.4% 0.0% 1.0% 10
2010s 3.4% 1.0% 9.0% 10
2020s 15.0% 9.0% 22.0% 5

Countries ranked near Madagascar

  1. 136 Gambia 27.0% compare
  2. 136 Yemen 27.0% compare
  3. 138 Sudan 23.0% compare
  4. 140 Pakistan 14.0% compare
  5. 141 Afghanistan 7.0% compare

See the full ranking of 160 places →

More gender data for Madagascar

All data for Madagascar →

Frequently asked questions

What is access to anti-retroviral drugs, male in Madagascar?
Access to anti-retroviral drugs, male in Madagascar was 22.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Madagascar?
The highest recorded value was 22.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Madagascar?
The lowest recorded value was 0.0% in 2000.
How does Madagascar rank for access to anti-retroviral drugs, male?
Madagascar ranks 139th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Madagascar?
Over the last ten years it is up 1,000.0%. The long-run trend across the full record is volatile.
Where does this Madagascar data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Madagascar. Statizoid, drawing on UNAIDS estimates. Retrieved 08 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/madagascar/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/madagascar/">Access to anti-retroviral drugs, male in Madagascar</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.